[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Jean Perrin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":249},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,45,73,84,103,129,153,178,209,228],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053899","cdna-and-residual-disease-after-chemoradiotherapy-for-locally-advanced-head-and-neck-squamous-cell-carcinomas-100053899",false,"NCT07178847","cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas","Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma","NeckTAR-IN","Selection Criteria:\n\n* Patient included in NeckTAR study\n* Written informed consent signed for NeckTAR-IN study\n* Affiliation to the French social security system","ALL","18 Years","80 Years",{"count":21,"type":22},59,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.\n\nThe main question it aims to answer is :\n\n\\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).\n\nParticipants will :\n\n* be included in the main study (Neck-TAR)\n* have a blood sample 1 and 3-month after the end of treatment",[28],"Locally Advanced Head and Neck Carcinoma",[30,31],"circulating DNA","residual disease","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2025-10-13",{"date":40,"type":22},"2031-07",{"name":42,"class":43},"Centre Jean Perrin","OTHER",4,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100640857","phase-2-functional-imaging-of-digital-osteoarthritis-and-rheumatoid-arthritis-using-99mtc-ntp-15-5-in-nuclear-medicine-100640857","NCT07624994","Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine","Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study","CARSPECT II","Inclusion Criteria:\n\n* Karnofsky index \\> 70%\n* Obtaining written, signed and dated informed consent\n* Affiliation to a health insurance plan\n* For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period.\n* Ability and willingness to respect study visits, exams as well as protocol.\n\nRA Group:\n\n* certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR\u002FEULAR criteria,\n* symptomatic (finger pain \\> 4 \u002F10 on a numerical scale),\n* active synovitis (clinical and ultrasound),\n\nGroup DOA:\n\n* certain diagnosis of symptomatic DOA less than 5 years old (finger pain \\> 4 \u002F10 on a numerical scale),\n* stopping NSAIDs for at least 8 days before the injection,\n\nExclusion Criteria:\n\n* Ongoing use of non-steroidal anti-inflammatory drugs,\n* Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,\n* History of osteoarticular hand surgery.\n* History of hand soft tissue surgery in the past 6 months\n* Patients or patients 18 years old,\n* Pregnant or breastfeeding patient,\n* IMC\\>30,\n* History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,\n* Persons deprived of their liberty, under guardianship\u002Fcuratorship, or safeguarding of justice,\n* Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study.\n\nRA Group:\n\n* Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment.\n* Patients with a history of hand DOA",{"count":54,"type":22},80,[56],"PHASE2","This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis",[59],"Digital Osteoarthritis or Rheumatoid Arthritis",[61,62],"proteoglycan tracer","cartilage","NOT_YET_RECRUITING","2026-06-03",{"date":66,"type":36},"2026-06-04",{"date":68,"type":22},"2026-06-01",{"date":70,"type":22},"2028-07-01",{"name":42,"class":43},2,{"id":74,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":26,"conditions":77,"keywords":78,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":82,"locationsCount":83},"100606691",{"count":21,"type":22},[25],[28],[30,31],{"date":64,"type":36},{"date":38,"type":36},{"date":40,"type":22},{"name":42,"class":43},3,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":102,"locationsCount":44},"100493862","prediction-of-residual-disease-by-circulating-dna-detection-after-potentiated-radiotherapy-for-locally-advanced-head-and-neck-cancer-100493862","NCT05710679","Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer","NeckTAR","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years\n* Histologically confirmed, never treated squamous cell carcinoma with lymph node involvement\n* squamous cell carcinoma p16+or p16-, stage III (N1), IVa or IVb (UICC classification 8th edition), N1 minimum, and oropharyngeal sqamous cell carcinomas p16+ stage I or II, N1 minimum, resectable but not operated or unresectable, with indication for concomitant or sequential radiochemotherapy with induction chemotherapy using Docetaxel, Platinum, 5-Fluorouracil (TPF or modified TPF according to the practices of the investigating centers)\n* Oral cavity, oropharynx, hypopharynx or larynx, cervical adenopathies without primary\n* Availability of FFPE samples prior to treatment initiation\n* Detection of circulating DNA in the initial blood sample\n* Obtaining informed consent from the patient\n* Affiliation to the French social security system\n\nExclusion Criteria:\n\n* Tumor of the nasopharynx, sinuses, nasal cavity, salivary glands or thyroid cancer\n* Treatment by exclusive radiotherapy\n* Contraindication to cervical lymph node dissection\n* Metastatic disease (stage IVc)\n* Previous treatment for head and neck cancer\n* History of other cancer in the last 3 years (except carcinoma in situ, basal cell skin carcinoma, localized prostate cancer Gleason 6)\n* Pregnant or breastfeeding woman\n* Patient under guardianship or curators\n* Psychological disorder (cognitive disorders, vigilance disorders, etc.) or social reasons (deprivation of liberty by judicial or administrative decision) or geographical reasons that could compromise the medical follow-up of the trial or compliance with the treatment",{"count":92,"type":22},63,[25],"Sixty percent of newly diagnosed head and neck squamous cell carcinomas (HNSCCs) are at a locally advanced (LA) stage. Depending on tumor site, stage, and resectability, locoregional failure rates can range from 35% to 65%. The persistence of residual disease at the end of treatment is a major prognostic element but is not always reliably assessed by current imaging techniques. Up to 40-50% of patients have residual adenomegaly and only 30% have viable disease when further adenectomy is performed. Sensitive and reproducible detection of residual disease after treatment is a major challenge in this patient category.\n\n18F-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET\u002FCT) guided surveillance, with a negative predictive value of 95-97%, has proven to be non-inferior to cervical curage in HNSCCs with residual adenomegaly. Cervical curage is now indicated only if the response assessed by PET-CT is incomplete. Nevertheless, the ability of PET-CT to predict treatment failure is unsatisfactory due to a high frequency of false positives, because of inflammatory changes, with a positive predictive value of about 20-50%.\n\nCirculating tumor DNA (ctDNA) may provide a more reliable assessment of response to potentiated radiotherapy. Liquid biopsy monitoring of response in patients treated with potentiated radiation therapy for locally advanced HNSCCs a has been shown to be feasible. In 85% of patients, ctDNA is detectable and correlates significantly with tumor volume and response to treatment. In addition, one study showed that post-radiotherapy analysis of circulating HPV16 viral DNA (cvDNA) in patients with HPV16-related HNSCCs complemented PET-CT and helped guide management decisions. HPV16 cvDNA and PET-CT have similar negative predictive values, whereas the positive predictive value is higher for HPV16 cvDNA (100% versus 50%). Nevertheless, current data are insufficient to allow routine use of this marker.\n\nThis is a multicenter, single arm, open study for patients with a locally advanced head and neck cancer for which a potentiated radiotherapy is indicated.",[28],"2026-05-21",{"date":98,"type":36},"2026-05-26",{"date":100,"type":36},"2024-01-17",{"date":40,"type":22},{"name":42,"class":43},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":111,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100372720","xenografts-development-from-surgical-tumor-samples-of-patients-with-triple-negative-or-luminal-b-breast-cancer-100372720","NCT04133077","Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer","A Prospective Study of Xenografts Development From Samples Taken From Surgical Specimens of Patients With Triple Negative or Luminal B Breast Cancer","XenoBreast","Inclusion Criteria:\n\n* ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2\n* Signature of the participation consent to the study,\n* Affiliation to a social security scheme\n* Major woman with:\n\n  * metastatic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of neoadjuvant treatment\n  * metaplastic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, treated by primary surgery with a tumor size of at least 15 mm on the specimen.\n  * an inflammatory TN breast cancer (T4d), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.\n  * non-metaplastic or inflammatory TN breast cancer, histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.\n  * Luminal B breast cancer (LB), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.\n  * histologically proven metastatic TN or metastatic breast cancer with an operable metastasis whose residual size, after chemotherapy, is at least 10 mm on the specimen. Residual metastasis will be at least 15 mm on imaging.\n* Patients in a metastatic situation can be included regardless of the therapeutic line.\n\nExclusion Criteria:\n\n* Pregnant woman\n* Patient deprived of liberty by court or administrative decision\n* In neoadjuvant situation: no neoadjuvant treatment by radiotherapy or hormone therapy\n* Refusal to participate in the study","FEMALE",{"count":113,"type":22},85,[25],"Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the realization of such PDX (from primitive mammary tumors or after neoadjuvant treatment) would make it possible to have a better knowledge of the tumor heterogeneity to the therapeutic response, to explore the models of tumor evolution during metastatic progression and also observe the mechanisms of tumor resistance in the case of non-metastatic tumors. It therefore seems necessary to develop PDX from primitive tumors in order to observe firstly the success rate of PDX; on the other hand, the drift of the initial heterogeneity, measured by comparison of the histomolecular profile of the tumors with that of the PDXs. It aims to develop xenografts from tumor samples from surgical specimens of patients with triple negative or luminal B breast cancer.",[117],"Breast Cancer Female",[119],"PDX","2026-03-18",{"date":122,"type":36},"2026-03-19",{"date":124,"type":36},"2021-11-19",{"date":126,"type":22},"2030-08-31",{"name":42,"class":43},1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":128},"100558404","identification-of-new-candidate-genes-for-hereditary-predisposition-to-uveal-melanoma-100558404","NCT06550674","Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma","IGCMU","Inclusion Criteria:\n\n* Patient with a personal history of uveal melanoma (newly diagnosed, under treatment or in follow-up)\n* Enrolled in or benefiting from a social security scheme\n\nExclusion Criteria:\n\n* Causal pathogenic variation identified in BAP1 or MBD4\n* Patient does not consent to constitutional genetic analysis for diagnostic purposes\n* Patient not consenting to a constitutional genetic analysis for research purposes\n* Pregnant and breast-feeding women\n* Patients under guardianship or trusteeship",{"count":137,"type":22},50,[25],"Only 20% of familial uveal melanomas are explained by a hereditary predisposition, implying the presence of as yet unknown hereditary predispositions. This hypothesis is reinforced by epidemiological studies revealing an excess risk of prostate cancer, thyroid cancer and leukemia in patients who have developed uveal melanoma, even though these cancers are not part of the tumor spectrum of known hereditary predispositions to uveal melanoma (BAP1, MBD4). The identification of new candidate genes, once validated, would enable us to offer these families appropriate surveillance.",[141],"Uveal Melanoma",[143,144,145],"uveal melanoma","hereditary predisposition","candidate genes identification","2026-03-17",{"date":122,"type":36},{"date":149,"type":36},"2024-10-29",{"date":151,"type":22},"2028-04",{"name":42,"class":43},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":111,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":128},"100620734","identification-of-genetic-phenotypic-clinical-biological-and-histological-factors-differentiating-patients-with-ovarian-cancer-who-are-refractory-to-platinum-based-therapy-from-patients-defined-as-long-term-responders-to-platinum-based-therapy-100620734","NCT07361471","Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy","Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy.","ORTRAI","Inclusion Criteria:\n\n* Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.\n* Corresponding to one of the two groups below:\n\n  * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.\n  * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment\n* Affiliation to a social security scheme\n* Patient who signed the genetic consent form\n\nExclusion Criteria:\n\n* Minor patient\n* Pregnant patient\n* Patient under guardianship or conservatorship\n* Patients who object to the collection of their medical\u002Fparamedical data\n* Patient for whom the center does not have biological material for genomic analysis (FFPE block)\n* Patient under administrative, judicial decision or AME (State Medical Aid)",{"count":162,"type":22},55,[25],"After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.\n\nThe clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature.\n\nThe complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.",[166],"Ovarian Cancer",[168,169],"ovarian cancer","long responder","2026-02-18",{"date":172,"type":36},"2026-02-20",{"date":174,"type":36},"2026-01-22",{"date":176,"type":22},"2027-12-01",{"name":42,"class":43},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":186,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},"100562256","intrinsic-validity-of-molecular-markers-detection-on-tissular-tumoral-dna-to-predict-the-efficacy-of-177lutetium-psma-617-lu-psma-treatment-for-castration-resistant-metastatic-prostate-cancer-100562256","NCT06600802","Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer","Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer (PSMA-PRED)","PSMA-PRED","Inclusion Criteria:\n\n* Male \\>18 years of age\n* ECOG ≤ 2\n* Patient with histologically confirmed of metastatic castration resistant prostatic adenocarcinoma and with tumor biological material available (prostatic biopsies or prostatectomy)\n* Patient who received at least one taxane line and a second generation hormone therapy line\n* Patient receiving androgen deprivation therapy with serum testosterone \\\u003C 50 ng\u002FdL or \\\u003C 1.7 nmol\u002FL or having undergone surgical castration\n* Progressive mCRPC based based on at least 1 of the following criteria :\n\n  * Serum or plasma PSA progression defined as 2 consecutive increases in PSA measured at least 1 week prior. The minimal start value is 2.0 ng\u002FmL ; 1,0 ng\u002FmL is the minimal start value if confirmed increase in PSA is the only indication of progress\n  * Soft-tissue progression by RECIST 1.1 criteria\n  * Progression of bone disease : two new lesions ; only the positivity of bone scan defines metastatic bone disease, according to PCWG3 criteria.\n* Patients with at least one metastasis, bone and\u002For soft tissue and\u002For visceral, documented by the following methods in the 43 days prior to inclusion :\n\n  * Bone metastasis (regardless of location) highlighted by bone scan AND\u002FOR\n  * Lymph nodes metastasis, regardless of size and location; if the metastasis are only lymph nodes, the short axis of at least one node should be at least 15 mm AND outside the pelvis ; AND\u002FOR\n  * Visceral metastasis, regardless of size and location; a history of visceral metastasis at any time prior to randomization should be encoded as the presence of visceral metastasis at baseline (i.e., a patient with visceral metastasis prior ADT introduction which are disappeared at baseline will be counted as having visceral metastasis and will be considered to have a high tumor volume during stratification)\n* Patient with Lu-PSMA treatment indication, confirmed by PET 68Ga-PSMA-11. Eligibility for 68Ga-PSMA-11 PET is defined as:\n\n  * At least one lesion with a binding intensity greater than that of the liver parenchyma (definition of positivity),\n  * All lymph node lesions larger than 25 mm in the short axis must be positive on PSMA PET\n  * All bone metastases with a soft tissue component ≥ 10 mm in the largest diameter must be positive on PSMA-PET\n  * All solid organ metastases (e.g., lung, liver, adrenal glands, etc.) ≥ 10 mm in the largest diameter must be positive on PSMA-PET.\n* Adequate organ function :\n\n  * Bone marrow reserve :\n\n    * Absolute neutrophil count ≥ 1.5 x 10\\^9\u002FL\n    * Platelets ≥ 100 x 10\\^9\u002FL.\n    * Hemoglobin ≥ 9 g\u002FdL\n  * Hepatic function :\n\n    * Total bilirubin ≤ 2 x the upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤ 3 x ULN is permitted.\n    * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x ULN OR ≤ 5.0 x ULN for patients with liver metastases.\n    * Albumin \\> 2.5 g\u002FdL\n  * Renal function : Glomerular Filtration Rate (GFR) ≥ 50 mL\u002Fmin\u002F1.73m2 according to MDRD equation.\n* Obtaining the patient's free and informed consent\n* Social security scheme or beneficiary.\n\nExclusion Criteria :\n\n* Continuation of second-generation hormone therapy Patient\n* Other cancer in the last 3 years likely to change life expectancy or interfere with the assessment of the disease\n* Protected adult\n* History of somatic or psychiatric illness\u002Fcondition that may interfere with study objectives and evaluations\n* Patient unable to understand and comply with study instructions and requirements\n* ECOG \\> 2\n* Dilation of pyelocalicial cavities not previously supported\n* Obstruction of bladder discharge or uncontrollable and simultaneous urinary incontinence\n* Symptomatic spinal cord compression or clinical or radiological findings indicating imminent spinal cord compression\n* Fractured risk of bone damage\n* Active and symptomatic brain injury\n* Concurrent participation in a therapeutic trial and administration of any investigational agent within 28 days of inclusion\n* Metastatic tumor tissue as the only material available for prostate cancer diagnosis\n* Previous treatment with any of the following in the 6 months prior to inclusion : Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-cyclic irradiation\n* Previous treatment with radioligands targeting PSMA\n* Known hypersensitivity to one of the study treatments or its excipients or similar class drugs\n* Transfusion or use of bone marrow stimulating agents for the sole purpose of making a participant eligible for inclusion in the study","MALE",{"count":188,"type":22},120,[25],"Prostate cancer is the most common cancer in men. Its incidence is rising as the population ages. In the localized stage, the 5-year overall survival rate (OS) is 98%. Metastatic progression and resistance to castration have a negative impact on prognosis. Despite recent advances in management, the 5-year OS is around 30%. Therapeutic advances in this indication have been made mainly by the use of taxanes and second-generation hormone therapy. These treatments have improved OS and progression-free survival (PFS). They are now used as standard therapy.\n\nMore recently, the Phase III VISION trial confirmed the improvement in OS and radiological PFS achieved by treatment with the radioligand 177Lutetium-PSMA-617 (Lu-PSMA) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).\n\nThis treatment is currently available in early access in France. Despite encouraging results, 40% of patients will not respond to Lu-PSMA, and there are currently no validated predictive factors. Studies are currently on going, but the identification of biomarkers seems necessary to better stratify risk in these patients.\n\nNumerous tissue prognostic tests based on molecular characteristics or cell proliferation are emerging with this in mind. At present, molecular profiling is not a routine technique for prostate cancer, as it is for other solid cancers. At an early stage, the Decipher® Genomic classification tool has shown prognostic utility independently of therapeutic and clinico-pathological data.\n\nAccording to recent studies, methylome analysis would enable the subdivision of mCRPCs and could help identify new therapeutic targets.\n\nIn the metastatic phase, certain molecular abnormalities involving DNA repair genes are predictive of response to PARP inhibitors.\n\nMolecular analysis (mutations, copy number alterations, gene expression, DNA methylation) could therefore be useful in optimizing the management of mCRPC patients treated with Lu-PSMA.\n\nIf reliable molecular abnormalities are identified on tissue, a diagnostic technique based on circulating tumor DNA (ctDNA) analysis will be useful in decision-making for these patients. A biological collection will therefore be created during the course of this study, with a view to using ctDNA analysis in subsequent research.",[192,193],"Castration-resistant Metastatic Prostate Cancer","Treated by 177Lutetium-PSMA-617 (Lu-PSMA)",[195,196,197,198,199],"mCRPC","Lu-PSMA","biomarkers","response","prediction","2025-12-26",{"date":202,"type":36},"2025-12-31",{"date":204,"type":36},"2024-10-08",{"date":206,"type":22},"2034-06-30",{"name":42,"class":43},5,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":111,"minAge":18,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":128},"100555474","augmented-reality-feasibility-for-non-invasive-preoperative-tracking-in-breast-cancer-surgery-100555474","NCT06512558","Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery","AR-GBS","Inclusion Criteria:\n\n* Major women\n* Requiring conservative surgical management of a subclinical cancerous breast lesion (not palpable), the histology of which has been previously proven by anatomopathology;\n* Having a breast MRI indication at the time of the breast assessment performed at the Centre Jean Perrin\n* Ability to give informed consent to participate in the study,\n* Membership of a social security scheme\n\nExclusion Criteria:\n\n* Patients with breast neoplasia during pregnancy;\n* Persons deprived of their liberty or under guardianship or incapable of giving consent;\n* Refusal to participate.","100 Years",{"count":218,"type":22},20,[25],"Breast cancer is diagnosed by imaging at a non-palpable stage in more than half of all cases. Surgical removal requires preoperative guidance. Generally, preoperative guidance is performed using a metal guide under local anaesthetic and radiological control. This type of guidance has several limitations. For the patient, it can be painful and traumatic. The procedure involves two departments: radiology and the operating theatre, which poses logistical constraints. What's more, between 10% and 40% of patients require repeat surgery for unhealthy margins, raising the question of the effectiveness of the tracking procedure. The investigators propose to develop a non-invasive intraoperative guidance system: Augmented Reality, which will provide a 3D vision with virtual transparency of the breast during surgery, thanks to real-time fusion of preoperative imaging with video from a camera located in the operating room. The process is illustrated below.\n\nIllustration of the general principle of the augmented reality system for locating non-palpable breast lesions. The images above represent a preliminary test carried out on the computer outside the operating room. This is an initial research prototype which has not yet been validated and is not suitable for routine use.",[222],"Subclinical Breast Cancer Lesion",{"date":202,"type":36},{"date":225,"type":36},"2024-11-14",{"date":176,"type":22},{"name":42,"class":43},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":83},"100520871","impact-of-implementing-the-modified-a-diva-scale-on-successful-access-to-a-venous-line-on-the-first-attempt-100520871","NCT06062199","Impact of Implementing the Modified A-DIVA Scale on Successful Access to a Venous Line on the First Attempt","DIVAPERF","Inclusion Criteria:\n\n* Male or female patient of legal age included in a care program requiring a VVP;\n* Fluency in French\n* Patient affiliated to a social security scheme;\n* Written, signed and dated informed consent.\n\nExclusion Criteria:\n\n* As the A-DIVA scale specifies a search for venous access to the upper limb, any patient without an upper limb or with a condition that contraindicates VVP placement in the upper limbs will be excluded;\n* Patients treated as emergencies;\n* Patients with a language barrier or known significant cognitive or psychiatric disorders;\n* Patients under guardianship, curatorship, deprivation of liberty or legal protection;\n* Pregnant or breast-feeding women.",{"count":236,"type":22},200,[25],"Peripheral venous access (PVA), although commonly used, can be a difficult procedure for patients with precarious venous capital. The difficulty of insertion can lead to multiple attempts, with the consequences of pain, anxiety, delayed management and worsening of the potentially already precarious venous capital. One study assessed the risk of failure according to a score based on venous status criteria. This study first established a link between venous status criteria and the risk of failure. The criteria defined as determinants were used to establish a venous status score. The data were then repeated by analyzing the success rate as a function of the scale score. A clear link between score and risk of failure was established. It seems worthwhile to evaluate the impact of implementing this scale prior to the placement of a peripheral venous line.\n\nThe hypothesis is that obtaining a score predictive of failure would modify the therapeutic attitude of the registered nurse. They would opt for techniques that would increase their chances of success. This in turn would lead to a reduction in unsuccessful attempts, which generate pain and anxiety for the patient. Preserving venous capital by increasing first-attempt success is both a health issue for the patient and a guarantee of quality of care.",[240],"Chronic Disease","2025-04-03",{"date":243,"type":36},"2025-04-04",{"date":245,"type":36},"2024-02-27",{"date":247,"type":22},"2028-12",{"name":42,"class":43},""]